Ostarine

Ostarine (MK-2866, enobosarm) is a non-steroidal arylpropionamide-class SARM — a selective androgen receptor modulator. It binds the androgen receptor (AR) with high affinity but produces tissue-selective agonism: near-full agonist activity in skeletal muscle and bone, substantially weaker activity in prostate, skin, and scalp. That selectivity is the whole point of the class, and it's what separates the compound's practical risk/benefit from a comparable-dose oral AAS.

Tissue-Selective AR Agonism#

Testosterone and DHT activate the AR everywhere it's expressed — muscle, bone, prostate, sebaceous glands, scalp follicles. Ostarine's arylpropionamide scaffold binds the same AR but recruits a different coactivator profile depending on tissue. In myocytes and osteoblasts it drives full anabolic transcription; in prostate and androgenic tissue the coactivator recruitment is weak and gene expression is muted. The practical payoff: meaningful lean-mass gain without the prostate load, oily skin, or acceleration of androgenic alopecia that comes with supraphysiologic test.

"Patients in both enobosarm groups had significant increases in lean body mass compared with placebo, with no evidence of androgenic or estrogenic side-effects." — Dobs AS et al., The Lancet Oncology, 2013

Myofibrillar Protein Synthesis and Lean Mass#

AR activation in skeletal muscle drives the classical anabolic cascade — increased myofibrillar protein synthesis, satellite-cell activation, and improved nitrogen retention. Even at low clinical doses (3 mg/day), this translated to measurable, statistically significant lean-body-mass gain and improved stair-climb power in elderly subjects over 12 weeks. At community cut doses (20–25 mg/day), this is the mechanism doing the heavy lifting when ostarine preserves muscle in a caloric deficit.

"Increases in total lean body mass at 3 mg/day were statistically significant, and stair climb power improved significantly compared with placebo." — Dalton JT et al., Journal of Cachexia, Sarcopenia and Muscle, 2011

No Aromatization, No 5α-Reduction#

Ostarine is not a substrate for aromatase or 5α-reductase. It cannot convert to estradiol, and it cannot amplify into DHT in androgenic tissue. That's why the compound doesn't produce estrogenic water retention, gyno, or the aggressive hairline regression that high-dose test can trigger — and why an AI (anastrozole, aromasin) is not only unnecessary on an ostarine cycle but actively counterproductive. Your E2 is coming from your endogenous test, which ostarine is suppressing, so crashing estrogen on top of that is a joint-pain and libido disaster waiting to happen.

Osteoanabolic Effect on Bone#

AR activation in osteoblasts drives bone matrix formation. In orchiectomized rat models — the standard preclinical proxy for androgen-deficient bone loss — ostarine preserved cortical and trabecular architecture and improved mechanical strength. For lifters this matters in two contexts: long cycles in deep deficits (where bone density can erode) and older users layering ostarine on a TRT base.

"Ostarine treatment preserved both trabecular and cortical bone structure... contributing to higher mechanical bone strength in orchiectomized rats." — Komrakova M et al., Endocrine, 2023

HPG-Axis Suppression and Lipid Shift#

The same AR agonism that builds muscle also signals at the hypothalamus and pituitary. The brain reads "androgen is sufficient" and throttles GnRH, which blunts LH and FSH output, which shuts down endogenous testosterone production. This is dose- and duration-dependent — 10 mg for 8 weeks is mild, 25 mg for 10–12 weeks is reliably meaningful. Lipid impact follows the same curve: HDL drops (often 20–30% at 25 mg), LDL ticks up. Both reverse post-cycle, faster with a proper mini-PCT.

"HPG axis suppression has been documented with SARMs such as ostarine, and significant HDL reduction is not uncommon at recreational doses." — Burmeister MA, Fincher TK, Graham WH, US Pharmacist, 2020

This is the mechanism that makes PCT bloodwork non-negotiable at cut doses, and why "SARMs don't shut you down" is one of the most expensive myths in the community.

Common (most users)#

• HDL suppression — the most reliable finding on mid-cycle bloodwork. 20–30% drops at 25 mg are typical over 8–10 weeks. Reverses post-cycle. Mitigate with cardio, fish oil (3–4 g EPA/DHA daily), and keeping cycles to ≤10 weeks. Don't stack with other lipid-hostile orals.
• Mild HPG suppression — dose-dependent. 10 mg is barely noticeable; 25 mg reliably drops total T, LH, and FSH over 8+ weeks. Mini-PCT handles it.

"HPG axis suppression has been documented with SARMs such as ostarine, and significant HDL reduction is not uncommon at recreational doses." — Burmeister et al., US Pharmacist (2020)

• Week 1–2 lethargy / "flatness" — transient as the HPG axis downregulates and your endogenous production dips before ostarine's AR agonism takes over. Push through; it resolves by week 3. Don't bump the dose chasing it.
• Mild headaches — usually hydration-related or early-cycle. 3–4 L water/day, electrolytes, and it fades.
• Mild ALT/AST elevation — modest bumps (1.5–2× ULN) are common and typically return to baseline post-cycle. Worth tracking, not panicking over. Avoid alcohol and hepatotoxic orals on cycle.
• Appetite suppression — some users report it, useful in a cut, annoying in a recomp. No specific fix; eat on schedule.

Uncommon (dose-dependent or individual)#

• Meaningful ALT/AST elevation (>3× ULN) — back off or stop. Re-test in 2–4 weeks. More likely at 30 mg, longer cycles, or when stacked with other orals.
• LDL rise alongside HDL drop — if baseline lipids are already borderline, 25 mg for 10 weeks can push an ApoB panel into territory you don't want. Cut the cycle short if bloodwork moves hard.
• Deeper suppression at 25–30 mg over 12+ weeks — recovery stretches from 4–6 weeks out to 8–12 weeks. Run a proper SERM PCT, not just natural support.
• GI upset / loose stools — usually the PEG/ethanol carrier, not the molecule itself. Try a different vendor or take with food.
• Gyno-like nipple sensitivity — rare and paradoxical given ostarine doesn't aromatize. Usually occurs during PCT when the HPTA rebound transiently spikes estradiol. Manage with a SERM, not an AI.
• Mood changes / irritability — uncommon but reported. Check estradiol and total T; it's usually a rebound or suppression artifact, not the compound directly.

Rare but serious#

• Cholestatic drug-induced liver injury (DILI) — rare but documented, including full jaundice presentations. Warning signs: yellowing of skin/eyes, dark urine, pale stools, severe fatigue, right-upper-quadrant pain, persistent itching. Stop immediately and get LFTs. Risk concentrates in users stacking ostarine with superdrol, anadrol, or M1T, or running underdosed/contaminated product.

"We describe a case of severe drug-induced liver injury (DILI) after the use of the SARM, ostarine, presenting with jaundice and a cholestatic pattern of liver injury." — Flores et al., ACG Case Reports Journal (2021)

• Severe lipid derangement — HDL crashes below 20 mg/dL combined with LDL/ApoB spikes. Uncommon at 10–20 mg but possible in susceptible users on 25–30 mg, long cycles. Stop the cycle; don't try to ride it out.
• Prolonged HPTA recovery (>3 months) — rare on a single 25 mg cycle but real after back-to-back runs or 12-week cycles without PCT. If total T hasn't recovered by week 8 post, run a full SERM protocol and get a clinician involved.

Hard contraindications#

• Pregnancy or trying to conceive — teratogenicity is not characterized. Do not run.
• Pre-existing hepatic dysfunction or elevated baseline ALT/AST — don't start until liver values are in normal range.
• Concurrent hepatotoxic orals (superdrol, anadrol, M1T, high-dose winstrol) — this is where the DILI case reports cluster. Pick one oral, not two.
• Baseline dyslipidemia or untreated hypertension — get these managed before adding a compound that tanks HDL.
• Tested athletes in WADA / NCAA / IOC sport — ostarine has been on the Prohibited List since 2008 and the urine detection window runs weeks to months. The M1 metabolite assay is extremely sensitive. Do not risk it.

Gender-specific & PCT considerations#

Women: 5–10 mg/day is the proven female range. Virilization risk is meaningfully lower than oxandrolone at equivalent anabolic effect — which is why ostarine has genuine traction in female physique prep. Still, monitor for clitoral sensitivity, voice deepening, or unusual aggression, and discontinue immediately if they appear. Cycle lengths at 5–10 mg for 6–8 weeks; don't push longer chasing more.

PCT: A 10 mg / 8-week cycle generally recovers on natural test support (sleep, zinc, creatine, DAA if you like it). A 25 mg / 10-week cycle warrants a proper mini-PCT: Nolvadex 20/20/10/10 or Clomid 25 mg/day × 4 weeks. Pull bloodwork at baseline, mid-cycle (week 4–5), and 4 weeks post — total/free T, LH, FSH, sensitive E2, full lipid panel, ALT/AST/GGT, CBC. Skipping the post-cycle draw is how people end up in trouble six months later without knowing why.